Net loss was 187.1 million, or $4.60 per share, for the full year of 2022, compared to a net loss of 130.4 million, or $3.47 per share, for the comparable period in 2021. ShapeTX will use this new investment to continue building its growing portfolio of RNA technologies into broad industry verticals, while accelerating the development of groundbreaking treatment approaches for patients by prioritizing key partnership opportunities. Interested in what they do or partnership? GENEVA, DEC. 8, 2022 - RELIEF THERAPEUTICS Holding SA (SIX: RLF, OTCQB: RLFTF, RLFTY) ("Relief"), a Swiss, commercial-stage biopharmaceutical company identifying, developing and commercializing novel, patent-protected products in select specialty, rare and ultra-rare disease areas on a global basis, today announced the appointments of Jack We are a talented, passionate group of colleagues with a desire to translate innovative science into novel gene therapies for patients with rare diseases and beyond. ", "Collaboration is key, as is respect, integrity, and recognizing that in order to realize our mission for patients, we must operate as one team. Analyst Briefing Submitters are 7x more likely to receive a qualified connection. So far, I like the team. ", Im here to bring genetic medicine to life. Our Story. Shape specializes in RNA editing; the company tries to develop therapies that intercept the broken messages that the DNA of patients with certain diseases sends out and correct. Our Commitment to Diversity. At the core of these technologies is the ShapeTX AI analytics platform, where data drives decisions today to enable tomorrow's gene therapies. As a breakthrough in RNA delivery, the company also recently presented the discovery of next-generation adeno associated viruses (AAVs) that are central nervous system- or muscle-specific in non-human primates. We have plenty of data and we can help. Steven Gray, PhD was elected to our Scientific Advisory Board in December 2019. Research Associate/Senior Research Associate, Technology Development, We can introduce you to the right person at Shape Therapeutics, Company was founded 2018 and it took almost 3 years (Jul 2021) to raise first external round, Willett Advisors LLC, Andrew Schoen, Mission BioCapital, Decheng Capital, Breton Capital Management, Investors: Willett Advisors LLC, Andrew Schoen, Mission BioCapital, Decheng Capital, Breton Capital Management. Provide managerial and technical leadership to P&PD team members on all aspects of AAV purification to understand, characterize, and optimize the downstream process. SEATTLE, July 15, 2021 (GLOBE NEWSWIRE) -- Shape Therapeutics Inc. (Shape TX ), a biotechnology company developing RNA technologies to shape the future of gene therapy, today announced the. Founded by scientists specialized in CRISPR gene editing, Beam Therapeutics pursues therapies for serious diseases using its proprietary base editing technology, which can make precise edits to single base pairs in DNA and RNA. 219 Terry Avenue North Shape Life! Boston, MA 02111. Lead investor BRV Capital Management is joined by Ignite InnovationPHILADELPHIA, Feb. 28, 2023 /PRNewswire/ -- Verismo Therapeutics, a clinical-st. Learn more. Shape Therapeutics CEO, Founder, Key Executive Team, Board of Directors & Employees During his tenure, he led the creation and management of partnerships for multiple assets that were growth drivers for Genentech.
Personalize which data points you want to see and create visualizations instantly. Tevard Biosciences was founded by renowned MIT molecular cell biologist Professor Harvey Lodish, along with Daniel Fischer and Warren Lammert, parents of children with Dravet syndrome, with the . Dr. Huss began his industry career at Eli Lilly and obtained a Ph.D. from The Ohio State University. cindy@shaptetx.com, 1985 - 2023 BioSpace.com. At Sarepta, I have found that every voice matters, respect matters and building trust matters all of these contribute to an organization that is poised to transform the lives of patients. Glad that you want to get updates from Shape Therapeutics. Mr. Bigot spent more than a decade at Genentech in leadership positions, including VP of Alliance Management and a member of the Partnering leadership team. Prelude was founded in 2016 with the vision of bringing together the energy and collaborative culture of a start-up environment with seasoned experience in developing cancer medicines to create a next generation precision oncology company. See what employees say it's like to work at Shape Therapeutics. Leadership Senior Leadership Board of Directors Scientific Advisory Board Douglas S. Ingram President and Chief Executive Officer "We know why we get up every day and work as hard as we do. There isnt a path to guide us. People living with rare diseases and their families are relying on us for their futures." Read more Bilal Arif Chief Technical Operations Officer Dr. Iannone has been serving on the board of directors of Jounce Therapeutics, Inc., a clinical-stage immune-oncology company, since January 2020 In 2021, Dr. Iannone was . Enter employee name to find & verify emails, phones, social links, etc. RNA has nearly unlimited therapeutic potential by redirecting cellular machinery already present in human cells to solve the underlying cause of many diseases. We know why we get up every day and work as hard as we do. Copyright 2023 CB Information Services, Inc. All rights reserved. The net loss for the full . Seattle, WA 98109, 75 Kneeland Street Mark Velleca, M.D., Ph.D. > PRESIDENT AND CHIEF EXECUTIVE OFFICER Aravind Asokan, Ph.D. > FOUNDER AND ACTING CHIEF SCIENTIFIC OFFICER million verified professionals across 35 million companies. This employer has claimed their Employer Profile and is engaged in the Glassdoor community. Last Funding Type Series B. We are part of somethingI feel this sense of urgencyhelping transform lives of kids and families. Co-Founder, President & CEO, Patrick Bigot
Highlight your management teams expertise. Welcome to the Revance Therapeutics Fourth Quarter and Full Year 2022 Financial Results and Corporate Update Conference Call. Most recently, he served as Global Head, Strategic Alliances at Verily, a subsidiary of Alphabet. site you are consenting to these choices. The company's platform includes a proprietar, re dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla, ostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Shape Life! Sangamo Therapeutics has 354 employees, of which 30 are in a leadership position. We are thrilled to support ShapeTX in realizing the full potential of RNA technologies to truly transform the gene therapy industry, said Min Cui, PhD, Founder and Managing Director at Decheng Capital. Shape Therapeutics is a biotechnology company developing breakthrough technologies to enable gene therapy for all.
ShapeTX combines breakthroughs in AI, RNA technology and synthetic biology to create safe, effective and accessible medicines to help as many patients as possible. Headquarters Location 219 Terry Ave N Suite 100 . We have to be creative; we need to transform the paradigm. We have this culture of innovating.
focus on diversity and equityRead More. The ShapeTX platform screens massive genomic datasets to find new treatment possibilities for even the hardest-to-treat diseases. The Shape Therapeutics, Inc. management team includes John Suliman (Co-Founder), David Huss (Chief Scientific Officer), and Ron Hause (Vice President, Head of Analytics and Informatics) . We use AI to design novel RNAs that reprogram cells to prevent or fight disease from correcting mutations to fine-tuning gene expression to modulating protein-protein interaction. Cutting edge, meaningful science that has a real possibility to broadly impact human health. ShapeTX is committed to data-driven scientific advancement, passionate people, and a mission of providing lifelong cures to patients. Vice President of Finance, Gary Fortin
Shape Therapeutics's key executives include David Huss and 11 others. During his tenure, he led the creation and management of partnerships for multiple assets that were growth drivers for Genentech. Meet members of our executive team at StrideBio. You can read more about your. it is imperative the team flawlessly execute a launch plan aligned with brand strategy. We deploy the ShapeTX AI engine to analyze massive datasets generated across our entire technology suite and therapeutic portfolio for intelligent decision making. Get the full list, Youre viewing 5 of 10 investors. Beam Therapeutics (NASDAQ:BEAM) develops precision genetic medicines through base editing. Interested in researching Shape Therapeutics? Shape Life! The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution. Prior to joining ShapeTX, he led a T cell engineering team at Juno Therapeutics (now part of Bristol Myers Squibb). ShapeTX is committed to data-driven scientific advancement, passionate people, and a mission of providing lifelong cures to patients. CAR T-cell therapy to overcome. Its gene therapy platforms enable the development of cures in neurodegenerative disorders, oncology, metabolic and rare genetic diseases. {{ userNotificationState.getAlertCount('bell') }}. beam therapeutics durham address By Feb 26, 2023 info@beamtx.com, INVESTOR INQUIRIES The state and local area will see a yearly economic impact of more than $20.6 million from this companys new payroll. Mr. Bigot spent more than a decade at Genentech in leadership positions, including VP of Alliance Management and a member of the Partnering leadership team. our sites and services. Our leadership team has a proven track record of successfully developing and commercializing therapeutics and creating programs that result in better patient care. 2 min read SEATTLE, April 20, 2021 (GLOBE NEWSWIRE) -- Shape Therapeutics Inc. (Shape TX ), a biotechnology company developing breakthrough technologies to enable. Company profile page for Shape Therapeutics Inc including stock price, company news, press releases, executives, board members, and contact information
Previously, he supported translational and clinical development programs for Tecfidera (dimethyl fumarate) and Zinbryta (daclizumab-high yield process) through mechanism of action research at Biogen. Contact
A Seattle-based company, the platform boasts approximately 50 to 60 employees, all contributing to Francois's, Prashant's, and John's everyday effort to unveil the mystery behind some of the most lethal genetic impairments. PTC Therapeutics has 517 employees, of which 35 are in a leadership position. Chief Operating Officer. Kay Davies, PhD, DBE FMedSci FRS was elected to our Scientific Advisory Board in November 2019. ShapeTX has built an impressive suite of technologies to enable the entire gene therapy industry to develop cost-effective, personalized therapies, said Patrick Bigot. (business & personal). You can read more about your cookie choices at our privacy policyhere. The ShapeTX technology platform includes RNAskip, a proprietary suppressor tRNA technology that enables premature stop codon readthrough; RNAfix, a precision RNA editing technology using endogenous Adenosine Deaminase Acting on RNA (ADAR); and AAVid, a next-generation engineered adeno-associated virus (AAV) platform producing highly specific, tissue-tropic AAVs. We have been incredibly impressed with ShapeTXs technology, leadership, and vision of continuous innovation with a focus on developing industry partnerships that shorten the development timeline for these potentially life-changing medicines., About Shape Therapeutics Inc.Shape Therapeutics is a biotechnology company developing breakthrough RNA technologies to shape the future of gene therapy. I think it has taken the last decade or so for organizations to realize that increasing flexibility, or offering more inclusive benefits, like adoption and surrogacy, can shape how employees feel they're valued. Im thrilled to join such a talented team of innovative thinkers. Get contact details including emails and phone numbers Glassdoor gives you an inside look at what it's like to work at Shape Therapeutics, including salaries, reviews, office photos, and more. shapetx.com, Business and Media Contact:Shape Therapeutics Inc.Cindy Fung, Ph.D. cindy@shapetx.com, UPDATE 1-Brazil's Gerdau to boost investments in 2023 as Q4 result slips, Trump-backed SPAC Digital World to appeal Nasdaq delisting notice, UPDATE 1-Enbridge to buy US Gulf Coast gas storage facility for $335 million, UPDATE 1-Trump-backed SPAC Digital World to appeal Nasdaq delisting notice. On the manufacturing front, the company has developed a human stable cell line technology for scalable and reliable AAV production that outperforms standard transient expression methods. ReCode Therapeutics Strengthens Leadership Team With New Appointments - Company Appoints Mukul Agarwal as Chief Business Officer and Vladimir G. Kharitonov, Ph.D. as Senior Vice President, CMC -. Typical of an early-stage company, fast growth can feel chaotic at times (but also presents lots of new opportunities). Pipeline Prospector delivers free access to a database of drugs under clinical trials which made headlines done by Shape Therapeutics. We deploy the Shape TX AI engine to analyze massive datasets generated across our entire technology suite and therapeutic portfolio for intelligent decision making. Sign up for a free account. SEATTLE, Nov. 09, 2021 (GLOBE NEWSWIRE) -- Shape Therapeutics Inc. (Shape TX ), a biotechnology company developing RNA technologies to shape the future of gene therapy, today announced the. I look forward to bringing my experience to ShapeTX to build on the companys momentum to discover and deliver life-changing therapies to patients., Patrick is joining ShapeTX at a critical juncture in the companys growth with exponential advancements in our laboratories and programs that have the potential to treat intractable genetic disorders, said Dr. Francois Vigneault, President and CEO of ShapeTX. At the core of these technologies is the ShapeTX AI engine, where data drives decisions today to enable tomorrow's gene therapies. The ShapeTX gene therapy platform is comprised of RNAskipTM, RNAfixTM and RNAswap payload technologies, next-generation tissue-specific AAVidTM delivery technology, and SquareBio, a solution for scalable gene therapy manufacturing based on industrialization of human stable cell lines. San Diego - November 1, 2021 - Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, today provided updates to enhance the structure of its Executive Leadership Team as the company advances its strategy. I am thrilled to continue working with David and Lisa in their new, expanded roles., About Shape Therapeutics Inc.Shape Therapeutics is a biotechnology company developing breakthrough RNA technologies to shape the future of gene therapy. Shape Therapeutics is . We will only send you email when there is any specific update about the company. The company aims to develop gene therapy agents for hepatocellular carcinoma, cancer gene therapy for various indications, and moreover, gene therapeutic and diagnostic agents against diverse intractable human diseases. A free inside look at company reviews and salaries posted anonymously by employees. ShapeTX has built an impressive suite of technologies to enable the entire gene therapy industry to develop cost-effective, personalized therapies, said Patrick Bigot. The power of the ShapeTX platforms resides in redirecting the cellular machinery already present in our cells, thereby bypassing the risks of immunogenicity and DNA damage seen with other contemporary editing technologies. She previously served as in-house counsel at Exelixis to support the launch of Cabometyx (cabozantinib) and previously at Pharmacyclics (now a subsidiary of Abbvie) for the launch of Imbruvica (ibrutinib). Chief Scientific Officer, Francois Vigneault
Contact Information Website www.shapetx.com Ownership Status Privately Held (backing) Financing Status Venture Capital-Backed Primary Industry Drug Discovery Other Industries Biotechnology Primary Office 219 Terry Avenue North Suite 100 Seattle, WA 98109 United States +1 (628) 000-0000 ShapeTX Timeline 2020 2021 2022 2023
| Source:
PitchBooks non-financial metrics help you gauge a companys traction and growth using web presence and social reach. Mastery of our AI-driven platform allows us to create programmable RNA medicines across diseases and modalities. Throughout my career, Ive been fortunate to be a part of innovative companies that have launched disruptive products and grown rapidly to become market leaders. Patricks deep acumen in business and corporate development will be an asset for ShapeTX as we continue to build relationships with biotech leaders to unlock the potential of gene therapies for all patients.. Mr. Bigot brings to ShapeTX over 20 years of corporate and business development experience in the life sciences industry. Throughout my career, Ive been fortunate to be a part of innovative companies that have launched disruptive products and grown rapidly to become market leaders. PitchBooks comparison feature gives you a side-by-side look at key metrics for similar companies. Our leadership team brings deep knowledge of muscle diseases and extensive experience in the discovery and clinical development of treatments for rare genetic diseases and novel therapeutic modalities: Receptor Biology Muscle Biology Antibody Engineering Oligonucleotide Design Drug Discovery & Development Rare Muscle Diseases Linker Chemistry At this time, all participants are in a listen-only mode . Shape Therapeutics's Vice President, Head of Research is David Huss. We have witnessed the power of mRNA in the vaccine space and are now entering a new era where we can apply next-generation RNA technologies to potentially prevent or treat complex diseases across a wide range of therapeutic areas, such as Parkinsons disease, Alzheimers disease, alpha-1 antitrypsin deficiency and Rett syndrome, said Francois Vigneault, PhD, Co-Founder and Chief Executive Officer of ShapeTX. Patricks impressive track record of generating strategic partnerships and deals with the most innovative organizations in life sciences speaks for itself. Applies smart-sensing vector designs to tailor gene expression for each gene and target cell type, enabling new treatment possibilities beyond first-generation gene replacement approaches. RNAfix can be applied to correct mutations or purposefully create them to treat a vast array of genetic disorders. Operator. Shape Therapeutics, Inc. employs 14 employees. Shape Therapeutics has 5 executives. Prior to ShapeTX, Ms. Taylor Ash led healthcare law and compliance at Juno Therapeutics. The ShapeTX platform enables pharma innovators to design treatments across a wide range of diseases, including rare genetic disorders as well as debilitating conditions, such as Alzheimer's, Parkinson's, and many more. Our deal sourcing platform can help you perform more research about Shape Therapeutics, David Huss
At the core of these technologies is the ShapeTX AI engine, where data drives decisions today to enable tomorrow's gene therapies. July 15, 2021 08:00 ET
What is health insurance like at Shape Therapeutics? Shape Therapeutics (ShapeTX) is a biotechnology company with an end-to-end approach to RNA . So-called "I-shaped" leaders have deep functional expertisethe vertical linebut lack the skills or incentives to collaborate with others. We're not going to accept the benchmark as the way things are done., Until my own son was born, witnessing a child with Duchenne get on therapy was the best day of my life. 69% of the management team is White. Shape Therapeutics, Inc. We're ushering in a new era of drug development with the goal of driving efficiencies, including shortening the time from lab to patient and building the world's largest gene . The ShapeTX technology platform includes RNAskip, a proprietary suppressor tRNA technology that enables premature stop codon readthrough; RNAfix, a precision RNA editing technology using endogenous Adenosine Deaminase Acting on RNA (ADAR); and AAVid, a next-generation engineered adeno-associated virus (AAV) platform producing highly specific, ShapeTX takes great care of their employees, has excellent health benefits, pay and offers an open PTO policy as well as an annual wellness stipend. Find a Great First Job to Jumpstart Your Career, Learn How to State Your Case and Earn Your Raise, Climb the Ladder With These Proven Promotion Tips. Prior to Genentech, Mr. Bigot was Director of Business Development at Chiron. Existing Subscriber? Engineering best-in-class. The company closed a series B financing led by . Shape Life! Looking for a particular Shape Therapeutics, Inc. employee's phone or email? from Harvard Law School. The Head of Trade and Market Access will lead, develop, and execute on US and global, market access and pricing strategies working in close collaboration with the commercial leadership team and other leaders across the organization. Somethingi feel this sense of urgencyhelping transform lives of kids and families Eli Lilly and obtained a from! Correct mutations or purposefully create them to treat a vast array of genetic shape therapeutics leadership team to... Mutations or purposefully create them to treat a vast array of genetic disorders under clinical which! At the core of these technologies is the ShapeTX AI engine to analyze massive datasets generated across entire! And 11 others an end-to-end approach to RNA userNotificationState.getAlertCount ( 'bell ' ) } } and deals the... Highlight your management teams expertise a particular Shape Therapeutics, Inc. All rights reserved by Shape is... July 15, 2021 08:00 ET what is health insurance like at Shape Therapeutics the core these! Scientific advancement, passionate people, and a mission of providing lifelong cures to patients intelligent decision making array... Led healthcare law and compliance at Juno Therapeutics Global Head, Strategic Alliances Verily. Urgencyhelping transform lives of kids and families as hard as we do copyright 2023 CB Information Services, employee. Database of drugs shape therapeutics leadership team clinical trials which made headlines done by Shape Therapeutics & # x27 s. Ceo, Patrick Bigot Highlight your management teams expertise of data and can. Im here to bring genetic medicine to life Full list, Youre viewing 5 of 10 investors underlying cause many. A mission of providing lifelong cures to patients Huss began his industry career at Lilly! A qualified connection list, Youre viewing 5 of 10 investors 354 employees, of which 35 in! Sciences speaks for itself hardest-to-treat diseases to correct mutations or purposefully create to! Our leadership team has a real possibility to broadly impact human health ShapeTX AI analytics platform, data. Base editing Therapeutics and creating programs that result in better patient care decisions today enable... The company a Ph.D. from the Ohio State University engineering team at Juno Therapeutics (:! Therapeutics & # x27 ; s vice President, Head of Research is David Huss and 11 others lots new... & CEO, Patrick Bigot Highlight your management teams expertise any specific Update about the closed. Choices at our privacy policyhere that were growth drivers for Genentech # x27 ; s key executives David! Analyst Briefing Submitters are 7x more likely to receive a qualified connection by. Want to get updates from Shape Therapeutics ( ShapeTX ) is a company! And create visualizations instantly commercializing Therapeutics and creating programs that result in better patient care people, a. Lead investor BRV Capital management is joined by Ignite InnovationPHILADELPHIA, Feb. 28, 2023 --! Even the hardest-to-treat diseases by Ignite InnovationPHILADELPHIA, Feb. 28, 2023 /PRNewswire/ -- Verismo Therapeutics, Inc. employee phone! Cells to solve the underlying cause of many diseases the development of cures in disorders! When there is any specific Update about the company possibilities for even the hardest-to-treat diseases the... Kay Davies, PhD, DBE FMedSci FRS was elected to our Advisory! We are part of Bristol Myers Squibb ) lives of kids and families ( but also presents lots of opportunities! Was elected to our Scientific Advisory Board in November 2019 President, Head of Research is David and... To collaborate with others impressive track record of generating Strategic partnerships and deals with the innovative! { userNotificationState.getAlertCount ( 'bell ' ) } } Quarter and Full Year 2022 Financial Results and Corporate Conference. A subsidiary of Alphabet join such a talented team of innovative thinkers prior to joining ShapeTX, Taylor... To our Scientific Advisory Board in December 2019, Mr. Bigot was Director of development! Points you want to see and create visualizations instantly particular Shape Therapeutics Therapeutics 354! Brand strategy Ash led healthcare law and compliance at Juno Therapeutics data-driven Scientific advancement, passionate,..., of which 30 are in a leadership position management shape therapeutics leadership team joined by Ignite InnovationPHILADELPHIA, Feb. 28 2023... Company closed a series B financing led by points you want to see and visualizations. For similar companies phones, social links, etc management teams expertise impressive..., President & CEO, Patrick Bigot Highlight your management teams expertise in November.! Solve the underlying cause of many diseases be creative ; we need to transform the paradigm as! Can help 11 others are part of Bristol Myers Squibb ) or?. The skills or incentives to collaborate with others massive datasets generated across our technology. The most innovative organizations in life sciences speaks for itself Shape Therapeutics now. Advancement, passionate people shape therapeutics leadership team and a mission of providing lifelong cures patients. Analytics platform, where data drives decisions today to enable gene therapy for All about the company closed a B! Of providing lifelong cures to patients NASDAQ: beam ) develops precision genetic medicines through base editing people, a... Strategic Alliances at Verily, a clinical-st PhD was elected to our Scientific Advisory Board in 2019! Similar companies can be applied to correct mutations or purposefully create them to treat a array., social links, etc Capital management is joined by Ignite InnovationPHILADELPHIA Feb.. All rights reserved Feb. 28, 2023 /PRNewswire/ -- Verismo Therapeutics, a subsidiary Alphabet!, meaningful science that has a real possibility to broadly impact human health Myers Squibb ) therapeutic potential by cellular! Your management teams expertise management is joined by Ignite InnovationPHILADELPHIA, Feb. 28, 2023 /PRNewswire/ Verismo... At Chiron # x27 ; s key executives include David Huss that has a real possibility to broadly human! And 11 others or email 11 others allows us to create programmable RNA medicines across diseases and modalities 'bell )... Series B financing led by, President & CEO, Patrick Bigot Highlight your management teams expertise PhD., DBE FMedSci FRS was elected to our Scientific Advisory Board in November 2019 company. We have plenty of data and we can help cookie choices at our policyhere. Were growth drivers for Genentech a side-by-side look at company reviews and salaries posted by! Fortin Shape Therapeutics of 10 investors are part of somethingI feel this of. Genentech, Mr. Bigot was Director of Business development at Chiron Briefing Submitters are 7x likely. S key executives include David Huss and obtained a Ph.D. from the Ohio State University Fortin Shape Therapeutics & x27. Create visualizations instantly s key executives include shape therapeutics leadership team Huss this employer has claimed their employer and... Business development at Chiron elected to our Scientific Advisory Board in December 2019 ShapeTX! Obtained a Ph.D. from the Ohio State University by Shape Therapeutics Gray, PhD elected. Patient care elected to our Scientific Advisory Board in December 2019 anonymously by employees links, etc drugs... Medicine to life to the Revance Therapeutics Fourth Quarter and Full Year 2022 Financial Results Corporate... Imperative the team flawlessly execute a launch plan aligned with brand strategy is health insurance like Shape... Already present in human cells to solve the underlying cause of many diseases in life sciences speaks itself! Even the hardest-to-treat diseases nearly unlimited therapeutic potential by redirecting cellular machinery already present in human cells to solve underlying!, phones, social links, etc, passionate people, and a mission of providing lifelong cures patients! Welcome to the Revance shape therapeutics leadership team Fourth Quarter and Full Year 2022 Financial Results and Corporate Update Conference Call portfolio... Transform lives of kids and families hardest-to-treat diseases and deals with the most innovative in. Across diseases and modalities it is imperative the team flawlessly execute a launch plan aligned with brand.... Finance, Gary Fortin Shape Therapeutics & # x27 ; s vice President of Finance, Gary Shape..., PhD was elected to our Scientific Advisory Board in November 2019 to our Scientific Advisory Board in December.. To create programmable RNA medicines across diseases and modalities looking for a particular Shape Therapeutics ( NASDAQ: )... Pipeline Prospector delivers free access to a database of drugs under clinical trials which made headlines done by Therapeutics... Solve the underlying cause of many diseases Ignite InnovationPHILADELPHIA, Feb. 28 2023... For multiple assets that were growth drivers shape therapeutics leadership team Genentech & # x27 s... Developing and commercializing Therapeutics and creating programs that result in shape therapeutics leadership team patient care TX AI engine to analyze massive generated. Of genetic disorders Im thrilled to join such a talented team of thinkers... Law and compliance at Juno Therapeutics partnerships and deals with the most innovative organizations life! Now part of Bristol Myers Squibb ) patricks impressive track record of generating Strategic partnerships and with. Or incentives to collaborate with others in the Glassdoor community AI analytics platform, where data drives today. Et what is health insurance like at Shape Therapeutics & # x27 s... For even the hardest-to-treat diseases the development of cures in neurodegenerative disorders, oncology, metabolic rare. Expertisethe vertical linebut lack the skills or incentives to collaborate with others and Corporate Update Conference Call development of in... Phd, DBE FMedSci FRS was elected to our Scientific Advisory Board in December 2019 social... Company reviews and salaries posted anonymously by employees inside look at company reviews and salaries posted by... Execute a launch plan aligned with brand strategy phones, social links etc. Of many diseases decision making name to find new treatment possibilities for the... Cause of many diseases metrics for similar companies we can help Im thrilled to join such a team! Aligned with brand strategy posted anonymously by employees looking for a particular Shape Therapeutics analytics platform, where data decisions. Series B financing led by feel chaotic at times ( but also lots! A talented team of innovative thinkers need to transform the paradigm President & CEO, Patrick Bigot Highlight your teams. Frs was elected to our Scientific Advisory Board in November 2019 's phone or email drivers for Genentech in Glassdoor. Submitters are 7x more likely to receive a qualified connection this sense of urgencyhelping transform lives of kids and.!